Peter Verdult

Stock Analyst at Citigroup

(0.30)

# 3,837

Out of 4,748 analysts

5

Total ratings

n/a

Success rate

n/a

Average return

Main Sectors:

Top Industries:

Drug Manufacturers - General Drug Manufacturers - Specialty & Generic Biotechnology

Stocks Rated by Peter Verdult

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	LLY Eli Lilly	Maintains: Buy	$1,250 → $1,190	$823.23	+44.55%	3	Jan 28, 2025
	EVO Evotec SE	Upgrades: Buy	n/a	$4.49	-	1	Jun 8, 2023
	GLPG Galapagos NV	Upgrades: Buy	n/a	$23.01	-	1	Jan 27, 2022

Eli Lilly

Jan 28, 2025

Maintains: Buy

Price Target: $1,250 → $1,190

Current: $823.23

Upside: +44.55%

Evotec SE

Jun 8, 2023

Upgrades: Buy

Price Target: n/a

Current: $4.49

Upside: -

Galapagos NV

Jan 27, 2022

Upgrades: Buy

Price Target: n/a

Current: $23.01

Upside: -